Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant
Hepatology2015Vol. 61(6), pp. 1880–1886
Citations Over TimeTop 1% of 2015 papers
Surakit Pungpapong, Bashar Aqel, Michael D. Leise, K. Tuesday Werner, Jennifer L. Murphy, Tanisha M. Henry, Kristen Ryland, Amy Chervenak, Kymberly D. Watt, Hugo E. Vargas, Andrew P. Keaveny
Abstract
An all-oral interferon-free antiviral regimen using simeprevir and sofosbuvir with or without RBV for 12 weeks was very well tolerated and resulted in excellent SVR12 rates in LT recipients with HCV genotype 1 infection.
Related Papers
- → Simeprevir and Sofosbuvir for Treatment of Chronic Hepatitis C Infection(2015)33 cited
- Recent advances in the treatment of hepatitis C.(2014)
- → Sofosbuvir-Daclatasvir-Simeprevir Plus Ribavirin in Direct-Acting Antiviral–Experienced Patients With Hepatitis C(2017)19 cited
- → Treatment with Sofosbuvir + Simeprevir for 12 Weeks in HCV Compensated Cirrhosis (Genotypes 1 and 4); The Use of Ribavirin Does Not Influence Sustained Viral Response(2016)1 cited
- → Faculty Opinions recommendation of Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis.(2015)